BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wen Y, Grandis JR. Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs 2015;20:313-29. [PMID: 25826749 DOI: 10.1517/14728214.2015.1031653] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Adem BF, Bastos NR, Dias F, Teixeira AL, Medeiros R. miRNAs: mediators of ErbB family targeted therapy resistance. Pharmacogenomics 2016;17:1175-87. [PMID: 27359187 DOI: 10.2217/pgs-2016-0038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
2 Hsueh WT, Chen SH, Chien CH, Chou SW, Chi PI, Chu JM, Chang KY. SOD2 Enhancement by Long-Term Inhibition of the PI3K Pathway Confers Multi-Drug Resistance and Enhanced Tumor-Initiating Features in Head and Neck Cancer. Int J Mol Sci 2021;22:11260. [PMID: 34681918 DOI: 10.3390/ijms222011260] [Reference Citation Analysis]
3 Mahmutović L, Bilajac E, Hromić-Jahjefendić A. Meet the Insidious Players: Review of Viral Infections in Head and Neck Cancer Etiology with an Update on Clinical Trials. Microorganisms 2021;9:1001. [PMID: 34066342 DOI: 10.3390/microorganisms9051001] [Reference Citation Analysis]
4 Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther 2016;16:847-58. [PMID: 27400139 DOI: 10.1080/14737140.2016.1202116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
5 Shen H, Yu X, Yang F, Zhang Z, Shen J, Sun J, Choksi S, Jitkaew S, Shu Y. Reprogramming of Normal Fibroblasts into Cancer-Associated Fibroblasts by miRNAs-Mediated CCL2/VEGFA Signaling. PLoS Genet 2016;12:e1006244. [PMID: 27541266 DOI: 10.1371/journal.pgen.1006244] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 7.0] [Reference Citation Analysis]
6 Tuomainen K, Hyytiäinen A, Al-Samadi A, Ianevski P, Ianevski A, Potdar S, Turunen L, Saarela J, Kuznetsov S, Wahbi W, Risteli M, Mäkitie A, Monni O, Salo T. High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Sci Rep 2021;11:14755. [PMID: 34285300 DOI: 10.1038/s41598-021-94259-5] [Reference Citation Analysis]
7 Thomas R, Weihua Z. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board. Front Oncol 2019;9:800. [PMID: 31508364 DOI: 10.3389/fonc.2019.00800] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
8 Keefe DMK, Bateman EH. Potential Successes and Challenges of Targeted Cancer Therapies. J Natl Cancer Inst Monogr 2019;2019:lgz008. [PMID: 31425592 DOI: 10.1093/jncimonographs/lgz008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 Warawdekar UM, Jain V, Patel H, Nanda A, Kamble V. Modifying gap junction communication in cancer therapy. Curr Res Transl Med 2021;69:103268. [PMID: 33069641 DOI: 10.1016/j.retram.2020.09.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Ma H, Jin S, Yang W, Zhou G, Zhao M, Fang S, Zhang Z, Hu J. Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma. Br J Cancer 2018;118:509-21. [PMID: 29348488 DOI: 10.1038/bjc.2017.442] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
11 Sun S, Zhang Z. Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization. Front Med 2016;10:104-10. [PMID: 26926009 DOI: 10.1007/s11684-016-0432-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
12 Grawish ME, Mourad MI, Esmaeil DA, Ahmed RA, Ateia IM, Hany E, Elkhier MTA. Emerging therapeutic modality enhancing the efficiency of chemotherapeutic agents against head and neck squamous cell carcinoma cell lines. Cancer Treat Res Commun 2020;25:100242. [PMID: 33249209 DOI: 10.1016/j.ctarc.2020.100242] [Reference Citation Analysis]
13 Kanazawa T, Misawa K, Misawa Y, Uehara T, Fukushima H, Kusaka G, Maruta M, Carey TE. G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer? Toxins (Basel) 2015;7:2959-84. [PMID: 26251921 DOI: 10.3390/toxins7082959] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
14 Vesci L, Milazzo FM, Anastasi AM, Petronzelli F, Chiapparino C, Carollo V, Roscilli G, Marra E, Luberto L, Aurisicchio L, Pacello ML, Spagnoli LG, De Santis R. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer. Oncotarget 2016;7:914-28. [PMID: 26575422 DOI: 10.18632/oncotarget.6089] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Kanazawa T, Misawa K, Shinmura K, Misawa Y, Kusaka G, Maruta M, Sasaki T, Watanabe Y, Carey TE. Promoter methylation of galanin receptors as epigenetic biomarkers for head and neck squamous cell carcinomas. Expert Rev Mol Diagn 2019;19:137-48. [PMID: 30640567 DOI: 10.1080/14737159.2019.1567334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
16 Tuomainen K, Al-Samadi A, Potdar S, Turunen L, Turunen M, Karhemo PR, Bergman P, Risteli M, Åström P, Tiikkaja R, Grenman R, Wennerberg K, Monni O, Salo T. Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing. Cancers (Basel) 2019;12:E92. [PMID: 31905951 DOI: 10.3390/cancers12010092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Li Z, Liao J, Yang Z, Choi EY, Lapidus RG, Liu X, Cullen KJ, Dan H. Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer. Br J Cancer 2019;120:306-16. [PMID: 30585254 DOI: 10.1038/s41416-018-0351-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wu C, Tong L, Wu C, Chen D, Chen J, Li Q, Jia F, Huang Z. Two miRNA prognostic signatures of head and neck squamous cell carcinoma: A bioinformatic analysis based on the TCGA dataset. Cancer Med 2020;9:2631-42. [PMID: 32064753 DOI: 10.1002/cam4.2915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
19 Sezer N, Arı İ, Biçer Y, Koç M. Superparamagnetic nanoarchitectures: Multimodal functionalities and applications. Journal of Magnetism and Magnetic Materials 2021;538:168300. [DOI: 10.1016/j.jmmm.2021.168300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Yang Z, Liao J, Lapidus RG, Fan X, Mehra R, Cullen KJ, Dan H. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma. Cancer Chemother Pharmacol 2022. [PMID: 35212780 DOI: 10.1007/s00280-022-04410-w] [Reference Citation Analysis]
21 Xu MJ, Johnson DE, Grandis JR. EGFR-targeted therapies in the post-genomic era. Cancer Metastasis Rev 2017;36:463-73. [PMID: 28866730 DOI: 10.1007/s10555-017-9687-8] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 17.0] [Reference Citation Analysis]